Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Arnold, Shanna A ^a,c   Rivera, Lee B ^a,d   Carbon, Juliet G ^a   Toombs, Jason E ^a   Chang, Chi Lun ^a   Bradshaw, Amy D ^b   Brekken, Rolf A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; OSTEONECTIN; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL PERMEABILITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROTEIN BINDING; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; CANCER INVASION; DRUG ANTAGONISM; METABOLISM; METASTASIS; MOUSE MUTANT; PANCREAS TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALIA; MUS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; LOSARTAN; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEONECTIN; PANCREATIC NEOPLASMS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84863127628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031384     Document Type: Article

References (64)

1. Ghaneh P, Costello E, Neoptolemos JP, (2007) Biology and management of pancreatic cancer. Gut 56: 1134-1152.
2. Bornstein P, (2002) Cell-matrix interactions: the view from the outside. Methods Cell Biol 69: 7-11.
3. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, et al. (1993) Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem 41: 1467-1477.
4. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, et al. (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 691-705.
5. Pen A, Moreno MJ, Martin J, Stanimirovic DB, (2007) Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia 55: 559-572.
6. Mendis DB, Ivy GO, Brown IR, (1998) SPARC/osteonectin mRNA is induced in blood vessels following injury to the adult rat cerebral cortex. Neurochem Res 23: 1117-1123.
7. Framson PE, Sage EH, (2004) SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92: 679-690.
8. Yan Q, Clark JI, Wight TN, Sage EH, (2002) Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice. J Cell Sci 115: 2747-2756.
9. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, et al. (2003) SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 120: 949-955.
10. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH, (1992) The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and-BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 89: 1281-1285.
11. Kupprion C, Motamed K, Sage EH, (1998) SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273: 29635-29640.
12. Hasselaar P, Sage EH, (1992) SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 49: 272-283.
13. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, et al. (2004) SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 91: 915-925.
14. Rivera LB, Brekken RA, (2011) SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-beta1 activity. J Cell Biol 193: 1305-1319.
15. Verrecchia F, Mauviel A, (2007) Transforming growth factor-beta and fibrosis. World J Gastroenterol 13: 3056-3062.
16. de la Cruz-Merino L, Henao-Carrasco F, Garcia-Manrique T, Fernandez-Salguero PM, Codes-Manuel de Villena M, (2009) Role of transforming growth factor Beta in cancer microenvironment. Clin Transl Oncol 11: 715-720.
17. Kelly RJ, Morris JC, (2009) Transforming growth factor-beta: A target for cancer therapy. J Immunotoxicol.
18. Schiemann BJ, Neil JR, Schiemann WP, (2003) SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 14: 3977-3988.
19. Ford R, Wang G, Jannati P, Adler D, Racanelli P, et al. (1993) Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: regulation via a TGF-beta-dependent pathway. Exp Cell Res 206: 261-275.
20. Reed MJ, Vernon RB, Abrass IB, Sage EH, (1994) TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 158: 169-179.
21. Pavasant P, Yongchaitrakul T, Pattamapun K, Arksornnukit M, (2003) The synergistic effect of TGF-beta and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. Arch Oral Biol 48: 717-722.
22. Wrana JL, Overall CM, Sodek J, (1991) Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 197: 519-528.
23. Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, et al. (2010) Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 3: 57-72.
24. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117-121.
25. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, et al. (2009) Circulating transforming growth factor-beta in Marfan syndrome. Circulation 120: 526-532.
26. Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, et al. (2008) Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 233: 860-873.
27. Macri L, Silverstein D, Clark RA, (2007) Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 59: 1366-1381.
28. Tufvesson E, Westergren-Thorsson G, (2002) Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett 530: 124-128.
29. Takeuchi Y, Kodama Y, Matsumoto T, (1994) Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 269: 32634-32638.
30. Hausser H, Groning A, Hasilik A, Schonherr E, Kresse H, (1994) Selective inactivity of TGF-beta/decorin complexes. FEBS Lett 353: 243-245.
31. Schonherr E, Broszat M, Brandan E, Bruckner P, Kresse H, (1998) Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch Biochem Biophys 355: 241-248.
32. Pardali E, ten Dijke P, (2009) Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci 14: 4848-4861.
33. Mumm JB, Oft M, (2008) Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 27: 5913-5919.
34. Agarwal R, Siva S, Dunn SR, Sharma K, (2002) Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 39: 486-492.
35. Laviades C, Varo N, Diez J, (2000) Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36: 517-522.
36. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
37. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, et al. (2008) Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358: 2787-2795.
38. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, et al. (2011) Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332: 361-365.
39. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, et al. (2011) Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332: 358-361.
40. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE, (2006) Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 339: 633-641.
41. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, et al. (2004) Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 286: F278-287.
42. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G, (2009) Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140-1151.
43. Nadal JA, Scicli GM, Carbini LA, Scicli AG, (2002) Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol 282: H739-748.
44. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, et al. (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111: 487-495.
45. Ostrand-Rosenberg S, Sinha P, (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
46. Galgani M, Di Giacomo A, Matarese G, La Cava A, (2009) The Yin and Yang of CD4(+) Regulatory T Cells in Autoimmunity and Cancer. Curr Med Chem.
47. Beyer M, Schultze JL, (2009) Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 15: 1879-1892.
48. Cao X, (2009) Regulatory T cells and immune tolerance to tumors. Immunol Res.
49. Wendt MK, Allington TM, Schiemann WP, (2009) Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5: 1145-1168.
50. Xu J, Lamouille S, Derynck R, (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.
51. An J, Nakajima T, Kuba K, Kimura A, (2010) Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 33: 831-835.
52. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, et al. (2009) Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 32: 12-21.
53. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, et al. (2010) Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16: 1191-1205.
54. Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, et al. (2009) Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 22: 355-360.
55. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK, (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 108: 2909-2914.
56. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
57. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L, (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536-1541.
58. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, et al. (2006) Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66: 6327-6335.
59. Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, et al. (2008) Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J Med Chem 51: 2302-2306.
60. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, et al. (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7: 829-840.
61. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, et al. (2003) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030.
62. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, et al. (1998) SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 39: 2674-2680.
63. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ, (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1: 50-62.
64. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC, (1995) Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 202: 325-332.